{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:16:05Z","timestamp":1792844165105,"version":"4.5.0"},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1097\/ftd.0000000000000716","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T17:36:12Z","timestamp":1576776972000},"page":"344-345","source":"Crossref","is-referenced-by-count":3,"title":["Delaying Centrifugation and Freezing by Adding a Dihydropyrimidine Dehydrogenase Inhibitor Such as Gimeracil to Blood Sample Is Not a Valid Option to Simplify the Preanalytic Step for the Screening of Dihydropyrimidine Dehydrogenase Deficiency Using Uracilemia"],"prefix":"10.1097","volume":"42","author":[{"given":"Manon","family":"Launay","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Toxicology and Blood Gases, University Hospital of Saint-Etienne, Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Nasser","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Blood Gases, University Hospital of Saint-Etienne, Saint-Etienne, France"},{"name":"Department of Biochemistry, University Hospital of Saint-Etienne, Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Tholance","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University Hospital of Saint-Etienne, Saint-Etienne, France"},{"name":"CNRS UMR 5310, INSERM U1217, Synaptopathies and Autoantibodies, Institut NeuroMyoGene, University of Lyon, University Jean-Monnet, Saint-\u00c9tienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Dellinger","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Blood Gases, University Hospital of Saint-Etienne, Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gonzalo","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University Hospital of Saint-Etienne, Saint-Etienne, France"},{"name":"CNRS UMR5286, INSERM U1052, Centre de Recherche en Canc\u00e9rologie de Lyon, Universit\u00e9 de Lyon, Centre L\u00e9on B\u00e9rard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Delavenne","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Blood Gases, University Hospital of Saint-Etienne, Saint-Etienne, France"},{"name":"INSERM, U1059, Dysfonction Vasculaire et H\u00e9mostase, Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1080\/17425255.2018.1550484","article-title":"How can we best monitor 5-FU administration to maximize benefit to risk ratio?","volume":"14","author":"Goirand","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"e0175998","DOI":"10.1371\/journal.pone.0175998","article-title":"New advances in DPYD genotype and risk of severe toxicity under capecitabine","volume":"12","author":"Etienne-Grimaldi","year":"2017","journal-title":"PLoS One."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/bjc.2017.94","article-title":"Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity","volume":"116","author":"Meulendijks","year":"2017","journal-title":"Br J Cancer."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1634\/theoncologist.2014-0132","article-title":"A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy","volume":"19","author":"Patel","year":"2014","journal-title":"Oncologist."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jpba.2016.04.039","article-title":"Development and validation of a rapid and sensitive UPLC-MS\/MS method for determination of uracil and dihydrouracil in human plasma","volume":"126","author":"Jacobs","year":"2016","journal-title":"J Pharm Biomed Anal."},{"key":"R6-20230814","first-page":"41","article-title":"Identification of a novel human uridine phosphorylase","volume":"307","author":"Johansson","year":"2003"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:38:14Z","timestamp":1692052694000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000716","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}